- Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudineJ Gauthier
Department of Virology, Glaxo Wellcome, Inc, Research Triangle Park, NC 27709, USA
J Infect Dis 180:1757-62. 1999..Thus, patients who respond to lamivudine therapy with dramatic reductions in viral DNA level (to <104 genomes/mL) appear more likely to seroconvert than patients who do not achieve this level of HBV clearance...
- Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudineM I Allen
Department of Virology, Inc, Research Triangle Park, North Carolina 27709 3398, USA
J Clin Microbiol 37:3338-47. 1999..These assays should prove useful for further understanding of virological response to therapy and disease progression...